BMS-986115 clinical trials
Also written varegacestat.
How each study uses BMS-986115 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2021 | 1 |
| 2024 | 1 |
| 2025 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Protease Inhibitors source
Studies
Open first, then newest update. How each study uses BMS-986115 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study of AL102 in Patients With Progressing Desmoid TumorsActive, not recruitingPhase 2/3Immunome, Inc.NCT04871282Written as AL102
- A Varegacestat Hepatic Impairment StudyCompletedPhase 1Immunome, Inc.NCT06841315Written as varegacestat
- A Phase 1 Mass Balance Study of VaregacestatCompletedPhase 1Immunome, Inc.NCT06845852Written as varegacestat
- A Cardiac Liability Study of Varegacestat in Healthy ParticipantsCompletedPhase 1Immunome, Inc.NCT06855264Written as varegacestat
- A Phase 1 Study to Examine the Effects of Itraconazole After Single Dose Administration of Varegacestat (AL102) to Healthy ParticipantsCompletedPhase 1Immunome, Inc.NCT06677996Written as varegacestat
- Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid TumorsTerminatedPhase 1Bristol-Myers SquibbNCT01986218Written as BMS-986115
Given beside what is tested · 1 — BMS-986115 is usual care or a partner of the new treatment
Codes
What other systems call BMS-986115 · ClinicalTrials.gg INT001110
- MeSH (NLM) C000631573BMS-986115One source NLM
- UNII (FDA) LSK1L593UUVAREGACESTATConfirmed FDA, NLM, Wikidata
- Wikidata Q27283163bms-986115Confirmed FDA, NLM, Wikidata
- DrugBank DB13126One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000631573 | BMS-986115 | One source NLM |
| UNII (FDA) | LSK1L593UU | VAREGACESTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27283163 | bms-986115 | Confirmed FDA, NLM, Wikidata |
| DrugBank | DB13126 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.